Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3
September 01, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
August 12, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Dosed the first patient in a potentially registrational Phase 2 trial of ZN-c3 in...
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
August 02, 2021 07:30 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
August 02, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of...
Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 01, 2021 16:01 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
June 28, 2021 21:09 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 28, 2021 16:18 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated
June 28, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an...
Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference
May 28, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...